Table 4

Longitudinal analyses on change in vitamin B12 (ΔB12) and change in’ FBG (ΔFBG) from baseline to exit visit*

ExposurenMean (SD)ΔFBG (μmol/L)
Non-adjusted modelAdjusted model†
ΔVitamin B12β (95% CI)P valueβ (95% CI)P value
Continuous (per IQR)4366−15.4 (299.5)0.02 (0.00 to 0.04)0.0180.01 (0.00 to 0.02)0.144
 Q11092−149.1 (155.3)00
 Q21091−38.4 (13.5)0.05 (−0.09 to 0.19)0.479−0.02 (−0.14 to 0.11)0.789
 Q310916.5 (13.5)0.23 (0.09 to 0.37)0.0010.11 (−0.01 to 0.24)0.082
 Q41092119.2 (545.2)0.34 (0.20 to 0.48)<0.0010.20 (0.08 to 0.33)0.002
P for trend<0.001<0.001
  • *This subsample included a total of 4366 subjects with both baseline and exit FBG and vitamin B12 measurements.

  • †Adjusted for age, sex, MTHFR gene C677T polymorphisms, SBP and DBP at baseline, mean SBP and DBP during the treatment period, body mass index, study center, baseline serum concentrations of folate, homocysteine, FBG, B12, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, treatment group, smoking status, alcohol consumption status, meat consumption, lipid-lowering drugs and antihypertensive drugs.

  • DBP, diastolic blood pressure; FBG, fasting blood glucose; MTHFR, methylenetetrahydrofolate reductase; SBP, systolic blood pressure.